Drug resistance among HIV and its "friends"

AIDS Reader

Volumn 13, Issue 3, 2003, Pages

  Laurence, Jeffrey ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Drug resistance; HAART; HIV AIDS; Viral load

Indexed keywords

ALPHA INTERFERON; LAMIVUDINE; RIBAVIRIN; VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; B LYMPHOCYTE; BIOAVAILABILITY; COHORT ANALYSIS; COST; ECONOMIC ASPECT; EDITORIAL; GENE EXPRESSION; GENE SILENCING; GOVERNMENT; HERPES VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; LIFESPAN; POLITICS; REDUCTION; RISK FACTOR; T LYMPHOCYTE; TUBERCULOSIS; VIREMIA; VIRUS LOAD; VIRUS REPLICATION; WILD TYPE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HUMANS; VIRAL LOAD;

EID: 0037344202     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (15)

1. Laurence J. Simplifying HIV therapeutics, and the global treatment of AIDS. AIDS Reader. 2003;13:5-6.
2. Kuritzkes DR, Boyle BA, Gallant JE, et al. Current management challenges in HIV: antiretroviral resistance. AIDS Reader. 2003;13:133-135,138-142.
3. Mocroft A, Phillips A, Reiss P, et al. Virological rebound after suppression on HAART: results from the EuroSIDA study. In: Program and abstracts of the 6th International Congress on Drug Therapy in HIV Infection; November 17-21, 2002; Glasgow, Scotland. Abstract PL5.4.
4. Persaud D, Zhou Y, Siliciano J, Siliciano RF. Latency in human immunodeficiency virus type 1 infection: no easy answers. J Virol. 2003;77:1659-1665.
5. Ruff CT, Ray SC, Kwon P, et al. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. J Virol. 2002;76:9481-9492.
6. Gunthard HF, Wong JK, Ignacio CC, et al. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol. 1998;72:2422-2428.
7. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385-394.
8. Hermankova M, Ray SC, Ruff M, et al. HIV-1 drug resistance profiles in children and adults with viral load < 50 copies/mL receiving combination therapy. JAMA. 2001;286:196-207.
9. Butterfield F. Infections in newly freed inmates are a rising concern. New York Times. January 28, 2003:A14.
10. Ristig MB, Crippin J, Aberg JA, et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis. 2002;186:1844-1847.
11. Nelson M, Portsmouth S, Stebbing J, et al. An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals. AIDS. 2003;17:F7-F10.
12. Stolberg SG. Bush proposal on AIDS funds shows concern about security. New York Times. January 29, 2003:A10.
13. Paterson DL, Swindels S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
14. Rosenberg T. Editorial Observer; In South Africa, a hero is measured by the advance of a deadly disease. New York Times. January 13, 2003:A20.
15. Levi GC, Vitoria MAA. Fighting against AIDS: the Brazilian experience. AIDS. 2002;16:2373-2383.